Psoriatic Arthritis

Latest News

Psoriatic Arthritis, Cardiovascular Health Improved With Etanercept Therapy

Psoriatic Arthritis, Cardiovascular Health Improved With Etanercept Therapy

The researchers noted that the small changes in lipid profile do not account for the cardiovascular benefits seen in patients taking etanercept.

Psoriasis Patients Have Higher Cardiometabolic Comorbidity Rates

Psoriasis Patients Have Higher Cardiometabolic Comorbidity Rates

Psoriasis patients have high rates hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.

Chronic Inflammatory Disorders May Increase Cardiometabolic, Mortality Risks

Chronic Inflammatory Disorders May Increase Cardiometabolic, Mortality Risks

The degree of risk for cardiometabolic events and all-cause mortality appeared to increase in participants who took nonsteroidal anti-inflammatory drugs or corticosteroid drugs.

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

Determining which patients are unlikely to respond to therapy early on may help reduce unnecessary treatment and contain costs.

Tofacitinib Found to Improve Nail Psoriasis

Tofacitinib Found to Improve Nail Psoriasis

There was improvement in nail psoriasis severity at 16 weeks compared with placebo that was maintained through 52 weeks.

Serum Amyloid A Levels May Act as Biomarker for Disease Activity in Psoriatic Arthritis

Serum Amyloid A Levels May Act as Biomarker for Disease Activity in Psoriatic Arthritis

Repeated serum amyloid A measurements could act as an additional marker for monitoring disease activity over time in patients with psoriatic arthritis.

No Negative Effect on Disease Activity Seen in Switching Patients to Biosimilar Infliximab From Originator Drug

No Negative Effect on Disease Activity Seen in Switching Patients to Biosimilar Infliximab From Originator Drug

Researchers found similar disease duration the 3 months before and after the switch to CT-P13 in patients.

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

Ixekizumab was found to benefit patients with psoriatic arthritis showing poor response to conventional treatment when administered over a 2- or 4-week period.

Risk for Endocrine Comorbidities Increased in Psoriatic Arthritis

Risk for Endocrine Comorbidities Increased in Psoriatic Arthritis

Researchers evaluated the prevalence of several endocrine disorders in patients with psoriatic arthritis.

GRAPPA-OMERACT: PsA Outcomes Measures Updated for Greater Inclusion of Patient Concerns

GRAPPA-OMERACT: PsA Outcomes Measures Updated for Greater Inclusion of Patient Concerns

The domains for outcome measurement in clinical trials of psoriatic arthritis were updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and endorsed by Outcome Measures in Rheumatology.

Sign Up for Free e-newsletters